ArticleInternational journal of women's health2025
Partial Response Achieved in a Case of Metastatic Triple-Negative Breast Cancer Based on the Patient-Derived Tumor Organoids.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of triple-negative breast cancer (TNBC) is dismal due to aggressive behaviors. Emergence of patient-derived tumor organoids (PDTOs) allows for biomarker identification and drug screening to identify potential drugs at the patient-specific level. Here, we described a case of metastatic TNBC who obtained partial response in the liver metastatic lesions after treatment with sacituzumab govitecan that was identified highly sensitive by the PDTOs. Case Presentation: A 50-year-old woman visited our hospital for re-examination due to over 9 years after surgery for the left breast cancer. In February 2024, she experienced liver metastasis. In combination with medical history and immunohistochemistry results, metastatic TNBC was diagnosed. Based on the PDTO drug sensitivity testing, the patient was treated with highly sensitive sacituzumab govitecan. After 6 cycles of treatment, liver metastatic lesions were reduced partially. Conclusion: In our case of TNBC, partial response is achieved in the liver metastatic lesions after treatment based on the PDTOs, unveiling that the PDTO, a potential companion tool for selection of treatment options, can facilitate the personalized treatment in metastatic TNBC patients to improve the prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.